In this issue of Medical Clinics of North America, guest editors Drs. Anand V. Kulkarni and K. Rajender Reddy bring their considerable expertise to the topic of Hepatology: An Update. Top experts in the field cover key topics such as NAFLD; hepatic manifestations of a systemic illness; cirrhosis and portal hypertension; hepatic encephalopathy; ICU care of the patient with cirrhosis; hepatocellular carcinoma; liver transplantation for the non-hepatologist; and more. Contains 15 relevant, practice-oriented topics including the global burden of chronic liver disease; the rising epidemic of alcoholic hepatitis; inpatient hepatology consultation; frailty and sarcopenia; and more. Provides in-depth clinical reviews on hepatology, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

There are over 180 million people with chronic HCV infection worldwide with between 2.7 and 3.9 million in the United States. Hepatitis C most significantly affects Asia and Africa, with rates up to 15% in countries such as Egypt and up to 30% in certain regions such as Punjab, Pakistan. Hepatitis C places a significant burden on the public health infrastructure, as it remains the leading cause of chronic liver disease, accounting for 50-75% of primary liver cancers and is responsible for 30% of all liver transplantations. It is estimated to have cost the United States $5.5 billion in 1997, comparable to the national cost of asthma, $5.8 billion in 1994.This number is only expected to grow as the current HCV population ages, increasing overall rates of compensated cirrhosis/end-stage liver disease. The evolution of directly acting anti-virals has ushered in a new era for chronic hepatitis C. Ongoing drug development strategy has involved targeting several replication steps of the virus and the hope is to see all oral therapies by late 2014 or early 2015. Thus we are at an exciting cross roads with regard to new information and challenges with HCV: rising disease burden with associated high costs, the challenges globally and in multiple patient populations, and the impending availability of effective and well tolerated treatments. Therefore there is a need to commission an exclusive issue of GCNA for HCV.

An essential resource for gastroenterologists, hepatologists, liver surgeons, hepatobiliary surgeons, oncologists, and all those working in the field of hepatocellular carcinoma (HCC), Hepatocellular Carcinoma: A Practical Approach covers the updates and recent developments on the diagnosis, screening, and comprehensive medical and surgical management of HCC.

This one-of-a-kind textbook explores all aspects of the disease using a practical, evidence-based approach, and provides step-by-step treatment guidelines that are applicable to all clinical scenarios.

Highlights in the text include:

• screening and surveillance methods to aid in the prevention of HCC
• imaging technologies for accurate diagnosis, including ultrasound and PET
• treatment modalities for HCC, such as local ablation therapy, chemoembolization, chemotherapy, and liver resection and transplantation
• a discussion on novel therapies and future therapeutic trends for treating HCC